Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
Study sponsor: Ultragenyx Pharmaceutical Inc · RARE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-08Estimated
Enrollment · participants41Estimated
Source updated2026-07-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.